



Bal Pharma Limited

To,

03.05.2017

The Manager-Listing Compliance
Bombay Stock Exchange Ltd
Mumbai.

National Stock Exchange of India Ltd
Mumbai.

Dear Sir,

Sub: Disclosure as per Regulation 30 of SEBI(LODR) Regulations, 2015.

With reference to the above and as per the provisions of Schedule III of SEBI(LODR) Regulations, 2015, we would like to disclose to the exchange that the Company has decided to issue notice as per the provisions of Section 25 FFA read with Section 25 F of the Industrial Disputes Act, 1947, pertaining to its parenterals and IV fluids manufacturing facility at Pune.

This decision was taken as part of the restructuring exercise undertaken by the Company to streamline its operations and to exit from its noncore businesses, whose operational costs are significant but generate very nominal revenues.

Please take this intimation on record.

Thanking You.

For Bal Pharma Limited

Sanjay Agarwal
Sanjay Kumar Agarwal
Company Secretary



CORPORATE OFFICE : 5th Floor, Lakshmi Narayan Complex, 10/1, Palace Road, Bengaluru - 560 052. India

Ph. : 91 - 80 - 41379500 Fax : 91 - 80 - 22354057/48

Email : info@balpharma.com Website : www.balpharma.com

CIN # L85110KA1987PLC008368

REGD. OFFICE & FACTORY : 21 & 22, Bommasandra Industrial Area, Bengaluru - 560 099. Ph: 41570813/19 Fax : 41570820